Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1981 1
1990 1
2005 1
2007 1
2008 2
2009 2
2010 1
2011 3
2012 1
2013 3
2014 4
2015 4
2016 3
2017 7
2018 10
2019 10
2020 14
2021 13
2022 12
2023 6
2024 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

88 results

Results by year

Filters applied: . Clear all
Page 1
Reply to M. Wissing et al.
Wiltink LM, Nout RA, Fiocco M, Creutzberg CL, Marijnen CAM. Wiltink LM, et al. Among authors: fiocco m. J Clin Oncol. 2017 Jun 1;35(16):1862. doi: 10.1200/JCO.2017.72.6125. Epub 2017 Mar 13. J Clin Oncol. 2017. PMID: 28549229 No abstract available.
Frailty and sarcopenia within the earliest national Dutch childhood cancer survivor cohort (DCCSS-LATER): a cross-sectional study.
van Atteveld JE, de Winter DTC, Pluimakers VG, Fiocco M, Nievelstein RAJ, Hobbelink MGG, Kremer LCM, Grootenhuis MA, Maurice-Stam H, Tissing WJE, de Vries ACH, Loonen JJ, van Dulmen-den Broeder E, van der Pal HJH, Pluijm SMF, van der Heiden-van der Loo M, Versluijs AB, Louwerens M, Bresters D, van Santen HM, Hoefer I, van den Berg SAA, den Hartogh J, Hoeijmakers JHJ, Neggers SJCMM, van den Heuvel-Eibrink MM; Dutch LATER study group. van Atteveld JE, et al. Among authors: fiocco m. Lancet Healthy Longev. 2023 Apr;4(4):e155-e165. doi: 10.1016/S2666-7568(23)00020-X. Lancet Healthy Longev. 2023. PMID: 37003274 Free article.
In the models for pre-frailty, underweight (odds ratio [OR] 3.38 [95% CI 1.92-5.95]) and obesity (OR 1.67 [1.14-2.43]), cranial irradiation (OR 2.07 [1.47-2.93]), total body irradiation (OR 3.17 [1.77-5.70]), cisplatin dose of at least 600 mg/m(2) (OR 3.75 [1.82-7.74]), gr …
In the models for pre-frailty, underweight (odds ratio [OR] 3.38 [95% CI 1.92-5.95]) and obesity (OR 1.67 [1.14-2.43]), cranial irradiation …
Cell-Free DNA as a Diagnostic and Prognostic Biomarker in Pediatric Rhabdomyosarcoma.
Lak NSM, van Zogchel LMJ, Zappeij-Kannegieter L, Javadi A, van Paemel R, Vandeputte C, De Preter K, De Wilde B, Chicard M, Iddir Y, Schleiermacher G, Ruhen O, Shipley J, Fiocco M, Merks JHM, van Noesel MM, van der Schoot CE, Tytgat GAM, Stutterheim J. Lak NSM, et al. Among authors: fiocco m. JCO Precis Oncol. 2023 Jan;7:e2200113. doi: 10.1200/PO.22.00113. JCO Precis Oncol. 2023. PMID: 36652664 Free PMC article.
Furthermore, 21 of 25 samples were correctly classified as embryonal by cfRRBS. RASSF1A-M was detected in 21 of 57 patients. The presence of RASSF1A-M was significantly correlated with poor outcome (the 5-year event-free survival [EFS] rate was 46.2% for 21 RASSF1A- …
Furthermore, 21 of 25 samples were correctly classified as embryonal by cfRRBS. RASSF1A-M was detected in 21 of 57 patients. The pres …
Outcome of Cataract Surgery in Patients With Retinitis Pigmentosa.
Nguyen XT, Thiadens AAHJ, Fiocco M, Tan W, McKibbin M, Klaver CCW, Meester-Smoor MA, Van Cauwenbergh C, Strubbe I, Vergaro A, Pott JR, Hoyng CB, Leroy BP, Zemaitiene R, Khan KN, Boon CJF. Nguyen XT, et al. Among authors: fiocco m. Am J Ophthalmol. 2023 Feb;246:1-9. doi: 10.1016/j.ajo.2022.10.001. Epub 2022 Oct 15. Am J Ophthalmol. 2023. PMID: 36252678 Free article.
Taste function in children: normative values and associated factors.
van den Brink M, IJpma I, Fiocco M, Tissing WJE, Havermans RC. van den Brink M, et al. Among authors: fiocco m. Pediatr Res. 2022 Oct;92(4):1175-1180. doi: 10.1038/s41390-021-01920-w. Epub 2021 Dec 28. Pediatr Res. 2022. PMID: 34963699 Free PMC article.
Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand?
Anninga JK, Gelderblom H, Fiocco M, Kroep JR, Taminiau AH, Hogendoorn PC, Egeler RM. Anninga JK, et al. Among authors: fiocco m. Eur J Cancer. 2011 Nov;47(16):2431-45. doi: 10.1016/j.ejca.2011.05.030. Epub 2011 Jun 22. Eur J Cancer. 2011. PMID: 21703851 Review.
Fifty single agent phase II studies showed high response rates for adriamycin (A, 43%), ifosfamide (Ifo, 33%), methotrexate (M, 32%), cisplatin (P, 26%) but only 4% for etposide (E). In 19 neo-adjuvant studies the mean 5-year event free survival (EFS) was 48% for 2-drug re …
Fifty single agent phase II studies showed high response rates for adriamycin (A, 43%), ifosfamide (Ifo, 33%), methotrexate (M, 32%), …
One-Year Outcomes After Transapical Echocardiography-Guided Mitral Valve Repair.
Colli A, Manzan E, Besola L, Bizzotto E, Fiocco A, Zucchetta F, Bagozzi L, Bellu R, Denas G, Pittarello D, Gerosa G. Colli A, et al. Among authors: fiocco a. Circulation. 2018 Aug 21;138(8):843-845. doi: 10.1161/CIRCULATIONAHA.118.033509. Circulation. 2018. PMID: 30359126 No abstract available.
Higher healing rate after meniscal repair with concomitant ACL reconstruction for tears located in vascular zone 1 compared to zone 2: a systematic review and meta-analysis.
Gerritsen LM, van der Lelij TJN, van Schie P, Fiocco M, van Arkel ERA, Zuurmond RG, Keereweer S, van Driel PBAA. Gerritsen LM, et al. Among authors: fiocco m. Knee Surg Sports Traumatol Arthrosc. 2022 Jun;30(6):1976-1989. doi: 10.1007/s00167-022-06862-2. Epub 2022 Jan 24. Knee Surg Sports Traumatol Arthrosc. 2022. PMID: 35072757 Free PMC article. Review.
Single-Center Experience with Ifosfamide Monotherapy as Second-Line Treatment of Recurrent/Metastatic Osteosarcoma.
Verschoor AJ, Speetjens FM, Dijkstra PDS, Fiocco M, van de Sande MAJ, Bovée JVMG, Gelderblom H. Verschoor AJ, et al. Among authors: fiocco m. Oncologist. 2020 Apr;25(4):e716-e721. doi: 10.1634/theoncologist.2019-0528. Epub 2019 Dec 19. Oncologist. 2020. PMID: 32297446 Free PMC article.
RESULTS: Sixty-two patients were selected with recurrent/metastatic osteosarcoma treated with second-line ifosfamide monotherapy (dose of 5 g/m(2) , n = 26; 9 g/m(2) , n = 36). OS was significantly better in univariate analysis for 9 g/m(2) compared with 5 g/ …
RESULTS: Sixty-two patients were selected with recurrent/metastatic osteosarcoma treated with second-line ifosfamide monotherapy (dose of 5 …
88 results